ZA202100101B - Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof - Google Patents

Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof

Info

Publication number
ZA202100101B
ZA202100101B ZA2021/00101A ZA202100101A ZA202100101B ZA 202100101 B ZA202100101 B ZA 202100101B ZA 2021/00101 A ZA2021/00101 A ZA 2021/00101A ZA 202100101 A ZA202100101 A ZA 202100101A ZA 202100101 B ZA202100101 B ZA 202100101B
Authority
ZA
South Africa
Prior art keywords
cdk4
inhibiting
activity
compound
crystal form
Prior art date
Application number
ZA2021/00101A
Inventor
Yiqian Wang
Chunhui Zhang
Jiabing Wang
Lieming Ding
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2019/092239 external-priority patent/WO2019242719A1/en
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of ZA202100101B publication Critical patent/ZA202100101B/en

Links

ZA2021/00101A 2018-06-21 2021-01-06 Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof ZA202100101B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2018092194 2018-06-21
PCT/CN2019/092239 WO2019242719A1 (en) 2018-06-21 2019-06-21 Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof

Publications (1)

Publication Number Publication Date
ZA202100101B true ZA202100101B (en) 2022-07-27

Family

ID=82558384

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/00101A ZA202100101B (en) 2018-06-21 2021-01-06 Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof

Country Status (1)

Country Link
ZA (1) ZA202100101B (en)

Similar Documents

Publication Publication Date Title
IL304526A (en) Manufacture of compounds and compositions for inhibiting the activity of shp2
IL280331A (en) Heterobicyclic compounds for inhibiting the activity of shp2
PT3468972T (en) Compounds and compositions for inhibiting the activity of shp2
IL271149A (en) Compounds for modulating s1p1 activity and methods of using the same
IL279579A (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
SG11202011513RA (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
ZA202106304B (en) Heterocyclic compound and use thereof
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
GB201820450D0 (en) Compound and its use for the treatment of alpha1-antitryspin deficiency
SG11202012289UA (en) Kdm1a inhibitors for the treatment of disease
EP3621615A4 (en) Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
IL277600A (en) Axl kinase inhibitors and use of the same
EP3787621A4 (en) Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
IL286697A (en) Neuregulin-4 compounds and methods of use
IL276912A (en) Heterocyclic compound and use thereof
IL308476A (en) Inhibitors of the menin-mll interaction
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
EP3816156A4 (en) Radioactive compound for treatment of melanoma and use thereof
EP3594198A4 (en) Use of dmso for the synthesis of oleacein and oleocanthal
ZA202100101B (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
IL290902A (en) The compounds to identify beta-lactamases, and methods of use thereof
ZA202101589B (en) Crystal form of tri-cycle compound and application thereof
EP4051270A4 (en) 4-amino-imidazoquinoline compounds and use thereof
SG11202104374WA (en) Heterocyclic compounds for the treatment of epilepsy
EP3604310A4 (en) Cdc-7-inhibitor compounds and use thereof for the treatment of neurological conditions